Metastatic Castration Resistant Prostate Cancer Clinical Trial identifier:
NCT03460977 (

This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.

Study Contact Information:

Learn More

About the Study

Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC).  This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment.  Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.

What the Study Involves

The study team will meet with you to see if you are eligible to participate in this study. At your initial screening visit, the study team will ask questions about your cancer diagnosis and medical history, perform a physical exam, laboratory tests, CT/MRI scans and electrocardiogram (ECG), and possibly take a biopsy of your tumor. 

 The study medicine, PF-06821497, is an oral tablet taken twice a day in 21-day cycles until your cancer has gotten worse, disappeared, or you decide to leave the study. You will be able to continue taking the study medicine as long as you and your doctor believe it is a benefit to you. You will need to attend regular visits so the study team can monitor how you are responding to the medicine. These visits will include health assessments, questionnaires, blood samples, ECGs, CT/MRI scans, and optional tumor biopsies. You will also be asked to track your dose schedule in a diary.

You can change your mind at any time if you feel this study isn’t right for you.

Learn more.

Study Locations

This is a global clinical research study. There are 64 study sites planned in 3 countries worldwide, including:

This Study is Open To:

Key Inclusion Criteria

This Study is Not Open To:

Key Exclusion Criteria


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.